MedPath

ADCT-901

Generic Name
ADCT-901

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2021-07-22
Last Posted Date
2025-05-22
Lead Sponsor
ADC Therapeutics S.A.
Target Recruit Count
30
Registration Number
NCT04972981
Locations
🇪🇸

Universidad Complutense de Madrid - Hospital Universitario 12 de Octubre, Madrid, Spain

🇬🇧

Imperial College Healthcare NHS Trust - St Mary's Hospital, London, England, United Kingdom

🇬🇧

Sarah Cannon Research Institute (SCRI) - London (SCRI-UK), London, England, United Kingdom

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath